Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Donghua Zhang
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07236931CT.gov Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Naïve AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells | — | Not Yet Recruiting | — | — | — |
NCT06900088CT.gov Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients | — | Not Yet Recruiting | — | — | — |
NCT06765928CT.gov Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT | — | Not Yet Recruiting | — | — | — |
NCT06613035CT.gov Twice-per-weekSelinexor, 2 Days Melphalan | — | Not Yet Recruiting | — | — | — |
NCT06265545CT.gov Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT07437170CT.gov Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML | — | Active Not Recruiting | — | — | — |
NCT05805072CT.gov Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients | — | Unknown | — | — | — |
NCT05736978CT.gov Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results | — | Recruiting | — | — | — |
NCT05951855CT.gov Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients | — | Unknown | — | — | — |
NCT05736965CT.gov A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia | — | Recruiting | — | — | — |
Show 16 more trialsShow fewer
NCT05726110CT.gov Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT04898894CT.gov Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03955783CT.gov Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies | — | Completed | — | — | — |
NCT03661515CT.gov Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML | — | Completed | — | — | — |
NCT03071276CT.gov Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02530476CT.gov Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02573363CT.gov Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02485535CT.gov Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant | — | Completed | — | — | — |
NCT02403310CT.gov A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | — | Completed | — | — | — |
NCT02416908CT.gov Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02299518CT.gov Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02249091CT.gov A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT02212561CT.gov Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT02091245CT.gov Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML | — | Active Not Recruiting | — | — | — |
NCT02093403CT.gov Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02088541CT.gov Selinexor (KPT-330) in Older Patients With Relapsed AML | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Selinexor (this asset) | Donghua Zhang | P3 | B · 58 |
| Gemtuzumab | M.D. Anderson Cancer Center | P4 | A |
| Amsacrine | University Hospital, Toulouse | P4 | BBB |
| Posaconazole | AstraZeneca | P4 | BBB |
| (+)-Vincristine | Janssen Research & Development, LLC | P3 | BBB |
| Aclacinomycin | Chinese PLA General Hospital | P4 | BB |
| Alvocidib | M.D. Anderson Cancer Center | P2 | BB |
| Prednisone | Children's Oncology Group | P3 | BB |
| Therapeutic Allogeneic Lymphocytes | University of Southern California | P2 | BB |
+42 more in the Acute Myeloid Leukemia cohort
Other indications for Selinexor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | — | P4 | BBB · 72 |
| Mantle Cell Lymphoma | — | P4 | BB · 70 |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Selinexor in Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/selinexor-acute-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →